The ACTIV-2 trial has begun testing the safety and efficacy of BRII-196 and BRII-198.

Tuesday, January 5, 2021 Large Clinical Trial Will Test Combination Monoclonal Antibody Therapy for Mild/Moderate COVID-19 A NIAID-sponsored clinical trial to evaluate a combination monoclonal antibody therapy for COVID-19 has begun to enroll people who have mild or moderate cases of the disease. The ACTIV-2 trial, which has previously tested the LY-CoV555 monoclonal antibody, has begun testing the safety and efficacy of BRII-196 and BRII-198, a pair of antibodies which are given together in IV infusions. Initially, the trial will enroll a small group of participants, and will then be expanded to enroll a larger group if a DSMB review indicates that that there are no serious safety concerns and the therapeutics may be effective. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107